A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 3, 2015, Pages 171-176

  Pemmaraju, Naveen ^a   Kantarjian, Hagop ^a   Kadia, Tapan ^a   Cortes, Jorge ^a   Borthakur, Gautam ^a   Newberry, Kate ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a   Jabbour, Elias ^a   Dellasala, Sara ^a   Pierce, Sherry ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Clinical study; JAK2V617 mutation; Janus kinase inhibitor; Myelofibrosis; Ruxolitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HYDROXYUREA; RUXOLITINIB; ANTINEOPLASTIC AGENT; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BRAIN EDEMA; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CELLULITIS; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONVALESCENCE; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG DOSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTIOUS COMPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG HEMORRHAGE; LUNG MYCOSIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; SEPSIS; THROMBOCYTOPENIA; TOXICITY TESTING; TOXICOLOGICAL PARAMETERS; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; BONE MARROW; CHROMOSOME ABERRATION; CLINICAL TRIAL; GENETICS; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MUTATION; PATHOLOGY; RECURRENT DISEASE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; CHROMOSOME ABERRATIONS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923611231     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.08.003     Document Type: Article

References (25)

1. R. Siegel, C. DeSantis, and K. Virgo Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241
2. A.K. Burnett Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program 2012 2012 1 6
3. N. Pemmaraju, H. Kantarjian, F. Ravandi, and J. Cortes FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer 117 2011 3293 3304
4. R.L. Levine, M. Wadleigh, and J. Cools Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 2005 387 397
5. E.J. Baxter, L.M. Scott, and P.J. Campbell Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 2005 1054 1061
6. R. Kralovics, F. Passamonti, and A.S. Buser A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
7. C. James, V. Ugo, and J.P. Le Couedic A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
8. J.J. O'Shea, S.M. Holland, and L.M. Staudt JAKs and STATs in immunity, immunodeficiency, and cancer N Engl J Med 368 2013 161 170
9. Z. Xiang, Y. Zhao, and V. Mitaksov Identification of somatic JAK1 mutations in patients with acute myeloid leukemia Blood 111 2008 4809 4812
10. E. Flex, V. Petrangeli, and L. Stella Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia J Exp Med 205 2008 751 758
11. V. Asnafi, S. Le Noir, and L. Lhermitte JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study Br J Haematol 148 2010 178 179
12. C.G. Mullighan, J. Zhang, and R.C. Harvey JAK mutations in high-risk childhood acute lymphoblastic leukemia Proc Natl Acad Sci U S A 106 2009 9414 9418
13. H.J. Lee, N. Daver, H.M. Kantarjian, S. Verstovsek, and F. Ravandi The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia Clin Cancer Res 19 2013 327 335
14. J.W. Lee, Y.G. Kim, and Y.H. Soung The JAK2 V617F mutation in de novo acute myelogenous leukemias Oncogene 25 2006 1434 1436
15. D.K. Walters, T. Mercher, and T.L. Gu Activating alleles of JAK3 in acute megakaryoblastic leukemia Cancer Cell 10 2006 65 75
16. T. Ikezoe, S. Kojima, and M. Furihata Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia Int J Cancer 129 2011 2512 2521
17. S. Verstovsek, H. Kantarjian, and R.A. Mesa Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 2010 1117 1127
18. S. Verstovsek, R.A. Mesa, and J. Gotlib A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
19. C. Harrison, J.J. Kiladjian, and H.K. Al-Ali JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
20. A. Eghtedar, S. Verstovsek, and Z. Estrov Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia Blood 119 2012 4614 4618
21. B.D. Cheson, J.M. Bennett, and K.J. Kopecky Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 2003 4642 4649
22. E. Atallah, J. Cortes, and S. O'Brien Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia Blood 110 2007 3547 3551
23. F. Ravandi, J. Cortes, and S. Faderl Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy Blood 116 2010 5818 5823 quiz 6153
24. A. Heine, P. Brossart, and D. Wolf Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122 2013 3843 3844
25. A. Heine, S.A. Held, and S.N. Daecke The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo Blood 122 2013 1192 1202